"[Doctors should] be informed that hair loss may be a potential side effect." "With this information, the risk-benefit trad ...

The versions affected are called compounded medications, which have the same active ingredients as the name brands. The ...

With two billion people overweight or obese and the obesity treatment market expected to reach $200 billion by 2031, Olio ...

Lexaria Bioscience (LEXX) announced pharmacokinetic results from Human Study #3 or GLP-1-H24-3, comparing an oral version of ...

More consistent accumulation demonstrated in bloodstream over a one-week duration with once-daily DehydraTECH-tirzepatide oral capsules as compared to once-weekly injection of Zepbound®As previously a ...

Addiction and obesity share deep neurological roots. Can new treatments like GLP-1 drugs and MEAI help break the cycle?

People without diabetes can lose up to 13% of their starting weight in 6 months using tirzepatide (Mounjaro) as an off-label ...

Ozempic and other similar drugs must be injected. Messer describes the needle as “small, the size of two human hairs.” ...

Detailed price information for Novo Nordisk A/S ADR (NVO-N) from The Globe and Mail including charting and trades.

Even a little weight loss can work wonders for your health. A study found that people at high risk for developing type 2 diabetes who lost 5-7% of their weight had a 58% lower risk of developing it.

"It's called GLP-1 receptor," said Dr. Atul Malhotra from the UC San Diego School of Medicine. It’s already FDA-approved to ...